ClearArc Capital’s AstraZeneca AZN Stock Holding History

ClearArc Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-11,036	Closed	-$716K	–	394
2014 Q1	$716K	Buy	+11,036	New	+$713K	0.18%	158

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MCM

Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ClearArc Capital's AZN Position: Q2 2014 in Review

ClearArc Capital sold out of AstraZeneca (AZN) in Q2 2014, closing a stake of 11,036 shares — an estimated $716K sold.

ClearArc Capital first reported a position in AZN in Q1 2014 and held it in 1 quarter. The position peaked at $716K in Q1 2014. 419 funds tracked by Wall St. Rank hold AZN as of Q2 2014.

ClearArc Capital reported no remaining AstraZeneca position as of Q2 2014 after selling out during the quarter.
ClearArc Capital sold 11,036 AstraZeneca shares in Q2 2014, an estimated $716K.
ClearArc Capital first reported a position in AstraZeneca in Q1 2014 and held it in 1 quarter.
ClearArc Capital's AstraZeneca position peaked at $716K in Q1 2014.
419 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2014.

Based on ClearArc Capital's 13F filing for Q2 2014, filed 14 Aug 2014.